Integer (ITGR) 10-Q 11 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 03, 2015	Aug. 11, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	GREATBATCH, INC.
Entity Central Index Key	1,114,483
Document Type	10-Q
Document Period End Date	Jul. 3, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--01-01
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		25,555,554

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Current assets:
Cash and cash equivalents	$ 72,338	$ 76,824
Accounts receivable, net of allowance for doubtful accounts of $1.3 million in 2015 and $1.4 million in 2014	122,101	124,953
Inventories	140,093	129,242
Refundable income taxes	2,368	1,716
Deferred income taxes	6,227	6,168
Prepaid expenses and other current assets	12,279	11,780
Total current assets	355,406	350,683
Property, plant and equipment, net	152,713	144,925
Amortizing intangible assets, net	58,572	65,337
Indefinite-lived intangible assets	20,288	20,288
Goodwill	354,107	354,393
Deferred income taxes	2,654	2,626
Other assets	22,391	17,757
Total assets	966,131	956,009
Current liabilities:
Current portion of long-term debt	13,750	11,250
Accounts payable	44,858	46,436
Income taxes payable	1,761	2,003
Deferred income taxes	588	588
Accrued expenses	37,670	48,384
Total current liabilities	98,627	108,661
Long-term debt	168,750	176,250
Deferred income taxes	51,087	53,195
Other long-term liabilities	6,065	4,541
Total liabilities	324,529	342,647
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding in 2015 or 2014	0	0
Common stock, $0.001 par value, authorized 100,000,000 shares; 25,592,286 shares issued and 25,544,985 shares outstanding in 2015; 25,099,293 shares issued and 25,070,931 shares outstanding in 2014	26	25
Additional paid-in capital	380,293	366,073
Treasury stock, at cost, 47,301 shares in 2015 and 28,362 shares in 2014	(2,279)	(1,307)
Retained earnings	256,739	239,448
Accumulated other comprehensive income	6,823	9,123
Total stockholders’ equity	641,602	613,362
Total liabilities and stockholders’ equity	$ 966,131	$ 956,009

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Jul. 03, 2015	Jan. 02, 2015
Current assets:
Allowance for doubtful accounts	$ 1.3	$ 1.4
Stockholders’ equity:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,592,286	25,099,293
Common stock, shares outstanding	25,544,985	25,070,931
Treasury stock, shares	47,301	28,362

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Income Statement [Abstract]
Sales	$ 174,890	$ 172,081	$ 336,210	$ 346,362
Cost of sales	116,939	113,611	225,861	230,296
Gross profit	57,951	58,470	110,349	116,066
Operating expenses:
Selling, general and administrative expenses	24,104	21,877	46,713	43,632
Research, development and engineering costs, net	13,063	12,793	25,608	26,324
Other operating expenses, net	7,750	4,261	15,605	4,047
Total operating expenses	44,917	38,931	87,926	74,003
Operating income	13,034	19,539	22,423	42,063
Interest expense	1,206	1,073	2,326	2,157
Other (income) expense, net	(107)	334	(1,658)	(287)
Income before provision for income taxes	11,935	18,132	21,755	40,193
Provision for income taxes	2,652	5,784	4,464	12,923
Net income	$ 9,283	$ 12,348	$ 17,291	$ 27,270
Earnings per share:
Basic	$ 0.36	$ 0.50	$ 0.68	$ 1.10
Diluted	$ 0.35	$ 0.48	$ 0.66	$ 1.06
Weighted average shares outstanding:
Basic	25,473	24,838	25,369	24,726
Diluted	26,313	25,901	26,264	25,823
Comprehensive Income
Net income	$ 9,283	$ 12,348	$ 17,291	$ 27,270
Foreign currency translation gain (loss)	214	(393)	(1,611)	789
Net change in cash flow hedges, net of tax	(89)	86	(689)	163
Other comprehensive income (loss)	125	(307)	(2,300)	952
Comprehensive income	$ 9,408	$ 12,041	$ 14,991	$ 28,222

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014
Cash flows from operating activities:
Net income	$ 17,291	$ 27,270
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,194	18,561
Debt related amortization included in interest expense	387	387
Stock-based compensation	5,972	6,729
Other non-cash gains, net	(19)	(3,896)
Deferred income taxes	(1,916)	(1,655)
Changes in operating assets and liabilities:
Accounts receivable	3,691	(10,741)
Inventories	(10,851)	(2,049)
Prepaid expenses and other current assets	(1,322)	(69)
Accounts payable	(848)	(2,106)
Accrued expenses	(7,239)	(8,967)
Income taxes	(846)	3,052
Net cash provided by operating activities	22,494	26,516
Cash flows from investing activities:
Acquisition of property, plant and equipment	(22,174)	(11,972)
Proceeds from sale of orthopaedic product lines (Note 9)	0	2,655
Purchase of cost method investments	(4,500)	(450)
Other investing activities	691	0
Net cash used in investing activities	(25,983)	(9,767)
Cash flows from financing activities:
Principal payments of long-term debt	(5,000)	(5,000)
Issuance of common stock	5,056	5,353
Other financing activities	(571)	(1,129)
Net cash used in financing activities	(515)	(776)
Effect of foreign currency exchange rates on cash and cash equivalents	(482)	(245)
Net increase (decrease) in cash and cash equivalents	(4,486)	15,728
Cash and cash equivalents, beginning of period	76,824	35,465
Cash and cash equivalents, end of period	$ 72,338	$ 51,193

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Equity - Unaudited - 6 months ended Jul. 03, 2015 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, shares at Jan. 02, 2015		25,099		(28)
Balance at Jan. 02, 2015	$ 613,362	$ 25	$ 366,073	$ (1,307)	$ 239,448	$ 9,123
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	4,659		4,659
Net shares issued under stock incentive plans, shares		493		(91)
Net shares issued under stock incentive plans	4,670	$ 1	9,109	$ (4,440)
Shares contributed to 401(k), shares				72
Shares contributed to 401(k) Plan	3,920		452	$ 3,468
Net income	17,291				17,291
Total other comprehensive loss, net	(2,300)					(2,300)
Balance, shares at Jul. 03, 2015		25,592		(47)
Balance at Jul. 03, 2015	$ 641,602	$ 26	$ 380,293	$ (2,279)	$ 256,739	$ 6,823

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jul. 03, 2015
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The January 2, 2015 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015 . The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The second quarter and year-to-date periods of 2015 and 2014 each contained 13 weeks and 26 weeks, respectively, and ended on July 3, and July 4, respectively.

Acquisition

Acquisition	6 Months Ended
	Jul. 03, 2015
Business Combinations [Abstract]
ACQUISITION	ACQUISITION On August 12, 2014 , the Company purchased all of the outstanding common stock of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”) , headquartered in Montevideo, Uruguay. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads. This acquisition allows the Company to more broadly partner with development stage medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts. This transaction was accounted for under the acquisition method of accounting. Accordingly, the operating results of CCC have been included in the Company’s QiG Group (“QiG”) segment from the date of acquisition. Once the medical devices developed by CCC for development stage companies receives regulatory approval and reaches significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. The aggregate purchase price of $19.8 million was funded with cash on hand. The cost of the acquisition was allocated to the assets acquired and liabilities assumed from CCC based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The valuation of the assets acquired and liabilities assumed from CCC was finalized during the first quarter of 2015 and did not result in a material adjustment to the original valuation of net assets acquired, including goodwill. The following table summarizes the allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Assets acquired Current assets $ 10,670 Property, plant and equipment 1,131 Amortizing intangible assets 6,100 Goodwill 8,296 Total assets acquired 26,197 Liabilities assumed Current liabilities 4,842 Deferred income taxes 1,590 Total liabilities assumed 6,432 Net assets acquired $ 19,765 The fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations. The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions. Current Assets and Liabilities – The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities. The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the market approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $0.3 million . Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands): Amortizing Intangible Assets Fair Value Assigned Weighted Average Amortization Period (Years) Weighted Average Discount Rate Technology $ 1,400 10 18% Customer lists 4,600 10 18% Trademarks and tradenames 100 2 18% $ 6,100 10 18% Technology – Technology consists of technical processes, unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by CCC and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 3% . The weighted average amortization period of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies. Customer Lists – Customer lists represent the estimated fair value of non-contractual customer relationships CCC has as of the acquisition date. The primary customers of CCC include medical device companies in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The weighted average amortization period of the existing customer base was based upon the historical customer annual attrition rate of 15% , as well as management’s understanding of the industry and product life cycles. Trademarks and Tradenames – Trademarks and tradenames represent the estimated fair value of corporate and product names acquired from CCC. These tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the trademarks and tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a 0.5% royalty rate. Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including: the value of CCC’s highly trained assembled work force and management team; the incremental value that CCC’s technology will bring to QiG’s medical devices; and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the CCC acquisition was allocated to the QiG business segment and is not deductible for tax purposes. Pro Forma Results The following pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Sales $ 174,890 $ 175,509 $ 336,210 $ 353,218 Net income 9,283 12,684 17,291 27,945 Earnings per share: Basic $ 0.36 $ 0.51 $ 0.68 $ 1.13 Diluted $ 0.35 $ 0.49 $ 0.66 $ 1.08 The results prior to the acquisition date have been adjusted to include the pro forma impact of the amortization of acquired intangible assets based on the purchase price allocations and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The pro forma consolidated basic and diluted earnings per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch. The pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings or any related integration costs. Certain cost savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained in the periods presented, or to be indicative of results that may be obtained in the future.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jul. 03, 2015
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Six Months Ended (in thousands) July 3, 2015 July 4, 2014 Noncash investing and financing activities: Common stock contributed to 401(k) Plan $ 3,920 $ 4,341 Property, plant and equipment purchases included in accounts payable 1,446 1,486

Inventories

Inventories	6 Months Ended
	Jul. 03, 2015
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are comprised of the following (in thousands): As of July 3, 2015 January 2, 2015 Raw materials $ 82,061 $ 73,354 Work-in-process 43,478 38,930 Finished goods 14,554 16,958 Total $ 140,093 $ 129,242

Intangible Assets

Intangible Assets	6 Months Ended
	Jul. 03, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS Amortizing intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Carrying Amount At July 3, 2015 Purchased technology and patents $ 95,776 $ (79,015 ) $ 1,966 $ 18,727 Customer lists 72,857 (34,974 ) 1,374 39,257 Other 4,534 (4,749 ) 803 588 Total amortizing intangible assets $ 173,167 $ (118,738 ) $ 4,143 $ 58,572 At January 2, 2015 Purchased technology and patents $ 95,776 $ (75,894 ) $ 1,966 $ 21,848 Customer lists 72,857 (31,460 ) 1,374 42,771 Other 4,534 (4,619 ) 803 718 Total amortizing intangible assets $ 173,167 $ (111,973 ) $ 4,143 $ 65,337 Aggregate intangible asset amortization expense is comprised of the following (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Cost of sales $ 1,445 $ 1,566 $ 2,916 $ 3,129 Selling, general and administrative expenses 1,830 1,717 3,643 3,434 Research, development and engineering costs, net 103 200 206 401 Total intangible asset amortization expense $ 3,378 $ 3,483 $ 6,765 $ 6,964 Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands): Estimated Amortization Expense Remainder of 2015 $ 6,222 2016 10,795 2017 9,520 2018 7,114 2019 5,431 Thereafter 19,490 Total estimated amortization expense $ 58,572 Indefinite-lived intangible assets are comprised of the following (in thousands): Trademarks and Tradenames At January 2, 2015 $ 20,288 At July 3, 2015 $ 20,288 The change in goodwill is as follows (in thousands): Greatbatch Medical QiG Total At January 2, 2015 $ 304,297 $ 50,096 $ 354,393 Foreign currency translation (286 ) — (286 ) At July 3, 2015 $ 304,011 $ 50,096 $ 354,107

Debt

Debt	6 Months Ended
	Jul. 03, 2015
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt is comprised of the following (in thousands): As of July 3, 2015 January 2, 2015 Variable rate term loan $ 182,500 $ 187,500 Revolving line of credit — — Total debt 182,500 187,500 Less current portion of long-term debt 13,750 11,250 Total long-term debt $ 168,750 $ 176,250 Credit Facility – The Company has a credit facility (the “Credit Facility”) that provides a $300 million revolving credit facility (the “Revolving Credit Facility”), a $182.5 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The Revolving Credit Facility can be increased by an additional $200 million upon the Company’s request and approval by the lenders. The Revolving Credit Facility has a maturity date of September 20, 2018 that may be extended to September 20, 2019 upon notice by the Company to the lenders and subject to satisfaction of certain conditions. The principal of the Term Loan is payable in quarterly installments as specified in the Credit Facility until its maturity date of September 20, 2019 , when the unpaid balance is due in full. The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories. Interest rates on the Revolving Credit Facility and Term Loan are, at the Company’s option either at: (i) the prime rate plus the applicable margin, which ranges between 0.0% and 0.75% , based on the Company’s total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranges between 1.375% and 2.75% , based on the Company’s total leverage ratio. Loans under the swingline subfacility will bear interest at the prime rate plus the applicable margin, which ranges between 0.0% and 0.75% , based on the Company’s total leverage ratio. The Company is also required to pay a commitment fee, which varies between 0.175% and 0.25% , depending on the Company’s total leverage ratio. The Credit Facility contains limitations on the incurrence of indebtedness, liens and licensing of intellectual property, investments, and certain payments. The Credit Facility permits the Company to engage in the following activities up to an aggregate amount of $300 million : 1) permitted acquisitions in the aggregate not to exceed $250 million ; 2) other investments in the aggregate not to exceed $100 million ; 3) stock repurchases and dividends not to exceed $150 million in the aggregate; and 4) investments in foreign subsidiaries not to exceed $20 million in the aggregate. At any time that the total leverage ratio of the Company for the two most recently ended fiscal quarters is less than 2.75 to 1.0, the Company may make an election to reset each of the amounts specified above. Additionally, these limitations can be waived upon the Company’s request and approval of a majority of the lenders. As of July 3, 2015 , the Company had available to it 100% of the above limits except for the aggregate and other investments limits, which are now $293 million and $93 million , respectively. The Credit Facility requires the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.5 to 1.0 decreasing to not greater than 4.25 to 1.0 after January 2, 2016 . The calculation of adjusted EBITDA and total leverage ratio excludes non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of July 3, 2015, the Company was in compliance with all covenants under the Credit Facility. The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable. As of July 3, 2015 , the weighted average interest rate on borrowings under the Credit Facility, which does not take into account the impact of the Company’s interest rate swaps, was 1.56% . As of July 3, 2015 , the Company had $300 million of borrowing capacity available under the Revolving Credit Facility. This borrowing capacity may vary from period to period based upon the debt and EBITDA levels of the Company, which impacts the covenant calculations described above. Interest Rate Swaps – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility. The variable rate received on the interest rate swaps and the variable rate paid on the debt have the same rate of interest, excluding the credit spread, indexed to the one-month LIBOR rate and reset and pay interest on the same date. During 2012, the Company entered into a three -year $150 million interest rate swap, which amortizes $50 million per year. During 2014, the Company entered into an additional interest rate swap. The first $45 million of notional amount of the swap was effective February 20, 2015 , and the second $45 million of notional amount is effective February 22, 2016 . The notional amount of the swap amortizes $10 million per year beginning on February 21, 2017 , with the remaining settled on the termination date of the swap agreement on September 20, 2019 . These swaps are being accounted for as cash flow hedges. Information regarding the Company’s outstanding interest rate swaps as of July 3, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Notional Amount Start Date End Date Pay Fixed Rate Current Receive Floating Rate Fair Value Balance Sheet Location Interest rate swap Cash flow $ 50,000 Feb 2013 Feb 2016 0.573 % 0.187 % $ (95 ) Accrued Expenses Interest rate swap Cash flow $ 90,000 Feb 2015 Sept 2019 1.921 % 0.187 % $ (1,488 ) Other Long-Term Liabilities The estimated fair value of the interest rate swap agreements represents the amount the Company expects to receive (pay) to terminate the contracts. No portion of the change in fair value of the Company’s interest rate swaps during the six months ended July 3, 2015 and July 4, 2014 was considered ineffective. The amount recorded as Interest Expense during the six months ended July 3, 2015 and July 4, 2014 related to the Company’s interest rate swaps was $0.5 million and $0.2 million , respectively. The expected future minimum principal payments under the Term Loan as of July 3, 2015 are as follows (in thousands): Remainder of 2015 $ 6,250 2016 16,250 2017 20,000 2018 20,000 2019 120,000 Total $ 182,500 Deferred Financing Fees – The change in deferred financing fees is as follows (in thousands): At January 2, 2015 $ 3,087 Amortization during the period (387 ) At July 3, 2015 $ 2,700

Benefit Plans

Benefit Plans	6 Months Ended
	Jul. 03, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
BENEFIT PLANS	BENEFIT PLANS The Company is required to provide its employees located in Switzerland, Mexico, and France certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age, and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The change in net defined benefit plan liability is as follows (in thousands): At January 2, 2015 $ 2,406 Net defined benefit cost 207 Foreign currency translation (164 ) At July 3, 2015 $ 2,449 Net defined benefit cost is comprised of the following (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Service cost $ 78 $ 52 $ 157 $ 104 Interest cost 15 20 30 39 Amortization of net loss 12 5 26 11 Expected return on plan assets (3 ) — (6 ) — Net defined benefit cost $ 102 $ 77 $ 207 $ 154

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jul. 03, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Stock options $ 663 $ 612 $ 1,282 $ 1,216 Restricted stock and restricted stock units 1,746 1,601 3,380 3,158 401(k) Plan stock contribution 1,310 1,339 1,310 2,355 Total stock-based compensation expense $ 3,719 $ 3,552 $ 5,972 $ 6,729 Cost of sales $ 1,094 $ 1,147 $ 1,354 $ 2,058 Selling, general and administrative expenses 2,148 1,998 3,909 3,921 Research, development and engineering costs, net 477 407 709 750 Total stock-based compensation expense $ 3,719 $ 3,552 $ 5,972 $ 6,729 The weighted average fair value and assumptions used to value options granted are as follows: Six Months Ended July 3, 2015 July 4, 2014 Weighted average fair value $ 12.18 $ 16.43 Risk-free interest rate 1.55 % 1.73 % Expected volatility 26 % 39 % Expected life (in years) 5 5 Expected dividend yield — % — % The following table summarizes time-vested stock option activity: Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 2, 2015 1,471,498 $ 25.32 Granted 301,547 49.20 Exercised (174,836 ) 23.41 Forfeited or expired (25,721 ) 37.94 Outstanding at July 3, 2015 1,572,488 $ 29.91 6.4 $ 37.1 Exercisable at July 3, 2015 1,115,959 $ 24.27 5.4 $ 32.6 The following table summarizes performance-vested stock option activity: Number of Performance- Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 2, 2015 118,839 $ 23.24 Exercised (50,255 ) 22.53 Outstanding at July 3, 2015 68,584 $ 23.76 3.0 $ 2.0 Exercisable at July 3, 2015 68,584 $ 23.76 3.0 $ 2.0 The following table summarizes time-vested restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 67,832 $ 36.22 Granted 42,497 49.52 Vested (8,831 ) 49.54 Forfeited (7,130 ) 42.15 Nonvested at July 3, 2015 94,368 $ 40.51 The following table summarizes performance-vested restricted stock and restricted stock unit activity: Performance- Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 716,163 $ 19.57 Granted 179,940 32.92 Vested (270,198 ) 15.30 Forfeited (25,599 ) 25.53 Nonvested at July 3, 2015 600,306 $ 25.24

Other Operating Expenses, Net

Other Operating Expenses, Net	6 Months Ended
	Jul. 03, 2015
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES, NET	OTHER OPERATING EXPENSES, NET Other Operating Expenses, Net is comprised of the following (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 2014 investments in capacity and capabilities $ 6,051 $ 2,166 $ 12,738 $ 2,218 Orthopaedic optimization costs 518 1,187 991 36 2013 operating unit realignment — 32 — 1,035 Other consolidation and optimization income, net — (10 ) — (71 ) Acquisition and integration costs (income) 98 47 164 (381 ) Asset dispositions, severance and other 1,083 839 1,712 1,210 $ 7,750 $ 4,261 $ 15,605 $ 4,047 2014 investments in capacity and capabilities. In 2014 , the Company announced several initiatives to invest in capacity and capabilities and to better align its resources to meet its customers’ needs and drive organic growth and profitability. These included the following: • Functions performed at the Company’s facility in Plymouth, MN to manufacture catheters and introducers will transfer into the Company’s existing facility in Tijuana, Mexico. This initiative is expected to be substantially completed by the first half of 2016 and is dependent upon our customers’ validation and qualification of the transferred products. • Functions performed at the Company’s facilities in Beaverton, OR and Raynham, MA to manufacture products for the portable medical market will transfer to a new facility in Tijuana, Mexico. This initiative is expected to be substantially completed by the end of 2015 and is dependent upon our customers’ validation and qualification of the transferred products. Products currently manufactured at the Beaverton facility, which do not serve the portable medical market, are planned to transfer to the Company’s Raynham facility. • The design engineering responsibilities previously performed at the Company’s Cleveland, OH facility were transferred to the Company’s facilities in Minnesota in 2014. • Realignment of the Company’s commercial sales operations. This initiative built upon the investment the Company has made in its global sales and marketing function and is expected to be completed during 2015. The total capital investment expected for these initiatives is between $ 25.0 million and $ 28.0 million , of which $17.0 million has been expended through July 3, 2015 . Total restructuring charges expected to be incurred in connection with this realignment are between $ 29.0 million and $ 34.0 million , of which $ 21.7 million has been incurred through July 3, 2015 . Expenses related to this initiative are recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following: • Severance and retention: $ 7.0 million - $ 9.0 million ; • Accelerated depreciation and asset write-offs: $ 2.0 million - $3.0 million ; and • Other: $ 20.0 million - $ 22.0 million Other expenses primarily consist of costs to relocate certain equipment and personnel, duplicate personnel costs, disposal and travel expenditures. All expenses are cash expenditures, except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ 1,163 $ — $ 1,066 $ 2,229 Restructuring charges 1,788 235 10,715 12,738 Write-offs — (235 ) — (235 ) Cash payments (949 ) — (10,328 ) (11,277 ) At July 3, 2015 $ 2,002 $ — $ 1,453 $ 3,455 Orthopaedic optimization costs. In 2010 , the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011. In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012. During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, in 2013, the Company sold assets related to certain non-core Swiss orthopaedic product lines to an independent third party. The purchase agreement provided the Company with an earn-out payment based upon the amount of inventory consumed by the purchaser within one year after the close of the transaction. As a result of this earn out, a gain of $2.7 million was recorded in Other Operating Expenses, Net in the first two quarters of 2014. During 2014, the Company transferred $2.1 million of assets relating to the Company’s Orvin, Switzerland property to held for sale and recognized a $0.4 million impairment charge in the fourth quarter of 2014. During the second quarter of 2015, the Company sold $0.6 million of these assets held for sale with no additional gain or loss recognized. During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next two years. The total capital investment expected to be incurred for these initiatives is between $30 million and $35 million , of which $25.4 million has been expended through July 3, 2015 . Total expense expected to be incurred for these initiatives is between $45 million and $48 million , of which $43.5 million has been incurred through July 3, 2015 . All expenses have been and will be recorded within the Greatbatch Medical segment and are expected to include the following: • Severance and retention: approximately $11 million ; • Accelerated depreciation and asset write-offs: approximately $13 million ; and • Other: $21 million – $24 million Other expenses include production inefficiencies, moving, revalidation, personnel, training, consulting, and travel costs associated with these consolidation projects. All expenses are cash expenditures, except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ — $ — $ 287 $ 287 Restructuring charges — 88 903 991 Write-offs — (88 ) — (88 ) Cash payments — — (1,034 ) (1,034 ) At July 3, 2015 $ — $ — $ 156 $ 156 2013 operating unit realignment. In 2013 , the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its former Implantable Medical and Electrochem Solutions reportable segments were combined into one sales and marketing group and one operations group each serving Greatbatch Medical. This initiative was completed during 2014. Total restructuring charges incurred in connection with this realignment were $6.6 million . Expenses related to this initiative were recorded within the applicable segment that the expenditures relate to and included the following: • Severance and retention: $5.0 million ; and • Other: $1.6 million Other expenses primarily consisted of relocation and travel expenditures. All expenses were cash expenditures. Acquisition and integration costs (income). During 2015 and 2014, the Company incurred costs (income) related to the integration of CCC and NeuroNexus Technologies, Inc. (“NeuroNexus”). These expenses were primarily for travel costs in connection with integration efforts, consulting, training, and the change in fair value of the contingent consideration recorded in connection with the NeuroNexus acquisition, which resulted in a gain of $0.6 million during the first six months of 2014. Asset dispositions, severance and other . During 2015 and 2014, the Company recorded losses in connection with various asset disposals. In addition, o n July 30, 2015, Greatbatch announced a proposed spin-off of a portion of its QiG segment (the “Spin-off”) , to be renamed Nuvectra Corporation (“Nuvectra”) upon completion of the Spin-off. Total legal and professional costs incurred in connection with the proposed Spin-off during the first six months of 2015 was $1.5 million . Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers to which the expenditures relate. If this proposed transaction is completed in 2015, deal related costs for the Spin-off are estimated to be between $10 million to $12 million for 2015. Refer to Note 15 “Business Segment, Geographic and Concentration Risk Information” for additional information on the proposed Spin-off. Dur ing 2014, the Company recorded $1.2 million of charges in connection with its business reorganization to align its contract manufacturing operations. Those costs primarily related to consulting and IT development projects, which were completed in the fourth quarter of 2014.

Income Taxes

Income Taxes	6 Months Ended
	Jul. 03, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. The 2015 GAAP effective tax rate for the first six months of 2015 was 20.5% compared to 32.2% for the same period of 2014. This decrease is primarily attributable to $1.0 million of favorable discrete tax items due to the settlement of tax audits in the first quarter of 2015, as well as higher income in lower tax rate jurisdictions. As of July 3, 2015 , the balance of unrecognized tax benefits is approximately $1.9 million . It is reasonably possible that a reduction of up to $0.5 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $1.5 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jul. 03, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation – The Company is a party to various legal actions arising in the normal course of business. While the Company does not expect that the ultimate resolution of any of these pending actions will have a material effect on its consolidated results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, does not become material in the future. Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability was comprised of the following (in thousands): At January 2, 2015 $ 660 Additions to warranty reserve 798 Warranty claims paid (102 ) At July 3, 2015 $ 1,356 Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms; however, these orders are normally cancelable without penalty. As of July 3, 2015 , the total contractual obligation related to such expenditures is approximately $39.1 million and will primarily be financed by existing cash and cash equivalents, cash generated from operations, or the Credit Facility. The Company also enters into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty. Operating Leases – The Company is a party to various operating lease agreements for buildings, machinery, equipment, and software. The Company primarily leases buildings, which accounts for the majority of the future lease payments. Minimum future estimated operating lease expenses are as follows (in thousands): Remainder of 2015 $ 3,077 2016 5,981 2017 3,910 2018 3,488 2019 3,418 Thereafter 13,937 Total estimated operating lease expense $ 33,811 Workers’ Compensation Trust – The Company was a member of a group self-insurance trust that provided workers’ compensation benefits to employees of the Company in Western New York (the “Trust”). Under the Trust agreement, each participating organization has joint and several liability for Trust obligations if the assets of the Trust are not sufficient to cover those obligations. During 2011, the Company was notified by the Trust of its intentions to cease operations at the end of 2011 and was assessed a pro-rata share of future costs related to the Trust. Based on actual experience, the Company could receive a refund or be assessed additional contributions for workers’ compensation claims insured by the Trust. Since 2011, the Company has utilized a traditional insurance provider for workers’ compensation coverage. Foreign Currency Contracts – The Company has entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its Tijuana, Mexico facility. The impact to the Company’s results of operations from these forward contracts was as follows (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Addition (reduction) in cost of sales $ 420 $ 8 $ 664 $ (156 ) Ineffective portion of change in fair value — — — — Information regarding outstanding foreign currency contracts as of July 3, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Aggregate Notional Amount Start Date End Date $/Peso Fair Value Balance Sheet Location FX Contract Cash flow $ 8,440 Jan 2015 Dec 2015 0.0734 $ (1,094 ) Accrued Expenses FX Contract Cash flow $ 1,574 Mar 2015 Dec 2015 0.0656 $ (61 ) Accrued Expenses FX Contract Cash flow $ 15,081 Jan 2016 Dec 2016 0.0656 $ (881 ) Accrued Expenses/Other Long-Term Liabilities Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The Company has specific stop loss coverage for claims incurred during 2015 exceeding $250 thousand per associate with no annual maximum aggregate stop loss coverage. As of July 3, 2015 , the Company had $1.4 million accrued related to the self-insurance of its medical plan. This accrual is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet and is primarily based upon claim history.

Earnings Per Share (EPS)

Earnings Per Share (EPS)	6 Months Ended
	Jul. 03, 2015
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”) The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Numerator for basic and diluted EPS: Net income $ 9,283 $ 12,348 $ 17,291 $ 27,270 Denominator for basic EPS: Weighted average shares outstanding 25,473 24,838 25,369 24,726 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 840 1,063 895 1,097 Denominator for diluted EPS 26,313 25,901 26,264 25,823 Basic EPS $ 0.36 $ 0.50 $ 0.68 $ 1.10 Diluted EPS $ 0.35 $ 0.48 $ 0.66 $ 1.06 The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met: Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Time-vested stock options, restricted stock and restricted stock units 276,000 179,000 297,000 179,000 Performance-vested restricted stock units 59,600 — 55,800 —

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jul. 03, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At April 3, 2015 $ (1,181 ) $ (3,480 ) $ 9,625 $ 4,964 $ 1,734 $ 6,698 Unrealized loss on cash flow hedges — (840 ) — (840 ) 295 (545 ) Realized loss on foreign currency hedges — 420 — 420 (147 ) 273 Realized loss on interest rate swap hedges — 281 — 281 (98 ) 183 Foreign currency translation gain — — 214 214 — 214 At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 2, 2015 $ (1,181 ) $ (2,558 ) $ 11,450 $ 7,711 $ 1,412 $ 9,123 Unrealized loss on cash flow hedges — (2,187 ) — (2,187 ) 766 (1,421 ) Realized loss on foreign currency hedges — 664 — 664 (232 ) 432 Realized loss on interest rate swap hedges — 462 — 462 (162 ) 300 Foreign currency translation loss — — (1,611 ) (1,611 ) — (1,611 ) At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At April 4, 2014 $ (672 ) $ (350 ) $ 16,134 $ 15,112 $ 505 $ 15,617 Unrealized gain on cash flow hedges — 18 — 18 (6 ) 12 Realized loss on foreign currency hedges — 8 — 8 (3 ) 5 Realized loss on interest rate swap hedges — 106 — 106 (37 ) 69 Foreign currency translation loss — — (393 ) (393 ) — (393 ) At July 4, 2014 $ (672 ) $ (218 ) $ 15,741 $ 14,851 $ 459 $ 15,310 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 3, 2014 $ (672 ) $ (468 ) $ 14,952 $ 13,812 $ 546 $ 14,358 Unrealized gain on cash flow hedges — 168 — 168 (59 ) 109 Realized gain on foreign currency hedges — (156 ) — (156 ) 55 (101 ) Realized loss on interest rate swap hedges — 238 — 238 (83 ) 155 Foreign currency translation gain — — 789 789 — 789 At July 4, 2014 $ (672 ) $ (218 ) $ 15,741 $ 14,851 $ 459 $ 15,310 The realized (gain) loss relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, respectively, in the Condensed Consolidated Statements of Operations.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 03, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. Foreign Currency Contracts – The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $1.5 million is expected to be realized within the next twelve months. Interest Rate Swaps – The fair value of the Company’s interest rate swaps outstanding at July 3, 2015 were determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s interest rate swaps will be realized as Interest Expense as interest on the Credit Facility is accrued. The following table provides information regarding liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Measurements Using At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Description 2015 (Level 1) (Level 2) (Level 3) Liabilities Foreign currency contracts (Note 11) $ 2,036 $ — $ 2,036 $ — Interest rate swap (Note 6) 1,583 — 1,583 — Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses, and current portion of long-term debt approximate fair value because of the short-term nature of these items. As of July 3, 2015 , the fair value of the Company’s variable rate long-term debt approximates its carrying value and is categorized in Level 2 of the fair value hierarchy. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first six months of 2015 or 2014 . Goodwill and Indefinite-lived Intangible Assets – Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero ” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples. Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. The Company did not record any impairment charges related to its indefinite-lived intangible assets, including goodwill, during the first six months of 2015 or 2014 , respectively. See Note 5 “Intangible Assets” for additional information on the Company’s intangible assets. Cost and Equity Method Investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other (Income) Expense, Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at July 3, 2015 and January 2, 2015 was $19.5 million and $14.5 million , respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of July 3, 2015 , the Company owned 7.3% of this fund. During the six month period ending July 3, 2015 and July 4, 2014 , the Company did not recognize any impairment charges related to its cost method investments. The fair value of these investments is determined by reference to recent sales data of similar shares to independent parties in an inactive market. This fair calculation is categorized in Level 2 of the fair value hierarchy. During the six month period ending July 3, 2015 and July 4, 2014 , the Company recognized a net gain on equity method investments of $0.5 million and $0.8 million , respectively.

Business Segment, Geographic an

Business Segment, Geographic and Concentration Risk Information	6 Months Ended
	Jul. 03, 2015
Segment Reporting [Abstract]
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION	BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION The Company has two reportable segments: Greatbatch Medical and QiG. Greatbatch Medical designs and manufactures medical devices and components where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices and components to the following markets: • Cardiac/Neuromodulation: Products include complete implantable medical devices and components such as batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures. • Orthopaedic: Products include implants, instruments and delivery systems for large joint, spine, extremity and trauma procedures. • Portable Medical: Products include automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools. • Vascular: Products include introducers, steerable sheaths, and catheters that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery. • Energy, Military, and Environmental: Products include primary and rechargeable batteries and battery packs for demanding applications such as down hole drilling tools. Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products. QiG is a medical device company formed in 2008 to develop and commercialize a neurostimulation technology platform for treatment of various disorders by stimulating tissues associated with the nervous system. QiG facilitates this development through the establishment of limited liability companies (“LLCs”). These LLCs do not own, but have the exclusive right to use the technology of Greatbatch in certain, specific fields of use and have an exclusive manufacturing agreement with Greatbatch Medical. QiG currently owns 89% of two LLCs - Algostim, LLC (“Algostim”) and PelviStim LLC (“PelviStim”). Minority interests in these LLCs are held by key opinion leaders and clinicians. Under the agreements governing these LLCs, QiG funds 100% of the expenses incurred by the LLC. No distributions are made to the minority holders until QiG is reimbursed for these expenses. Once QiG has been fully reimbursed, any potential future distributions will be applied first to return contributions made by minority partners and thereafter will be made pro rata based upon ownership percentages. Algostim is focused on the development and commercialization of its Algovita spinal cord stimulation (“SCS”) system (“Algovita”) , the first application of QiG’s neurostimulation technology platform. Algovita is indicated for the treatment of chronic pain of the trunk and limbs. Algovita was submitted for premarket approval (“PMA”) to the United States Food & Drug Administration (“FDA”) in December 2013 and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. CE Mark approval was obtained on June 17, 2014 . In April 2015, the Company announced receipt of a letter from the FDA informing it that its PMA application for Algovita is approvable subject to completion of an FDA inspection that finds that the manufacturing facilities, methods and controls used in the production of Algovita comply with the applicable requirements of the FDA’s Quality System Regulation. QiG expects to obtain final approval of its PMA application for Algovita during the second half of 2015 and to launch Algovita commercially in the United States shortly thereafter. QiG is also in the process of developing additional applications for its neurostimulation technology platform for other emerging indications such as sacral nerve stimulation (“SNS”), and deep brain stimulation (“DBS”), among others. QiG’s PelviStim subsidiary is focused on the commercialization of QiG’s neurostimulation technology platform for SNS. QiG revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets from NeuroNexus, and a limited release of Algovita in Europe. As further discussed in Note 2 “Acquisition,” in August 2014, the Company acquired CCC, a neuromodulation medical device developer and manufacturer for development stage companies. As a result of this transaction, QiG revenue for 2015 also includes sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. Once the medical devices developed by CCC for development stage companies receives regulatory approval and reaches significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. On July 30, 2015, Greatbatch announced a proposed spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group LLC subsidiary to the stockholders of Greatbatch on a pro rata basis. Immediately prior to completion of the Spin-off, QiG Group LLC will be converted into a corporation organized under the laws of Delaware and change its name to Nuvectra. The portion of the QiG segment being spun-off is expected to be comprised of QiG Group LLC and its subsidiaries: (i) Algostim, (ii) PelviStim, and (iii) Greatbatch’s NeuroNexus subsidiary. Upon completion of the Spin-off, Nuvectra will be an independent, publicly-traded company and Greatbatch will not own any shares of Nuvectra common stock but will retain the operations of QiG not spun-off, which includes CCC. The total financial impact of the Spin-off on the Company’s Condensed Consolidated Financial Statements cannot be determined at this time. However, if completed, deal related costs for the Spin-off are estimated to be between $10 million to $12 million for 2015. Additionally, o nce completed, the Spin-off is expected to deliver Greatbatch improved financial performance through its long-term manufacturing agreement with Nuvectra for the supply of Algovita and lower operating expenses estimated in the range of $12 million to $16 million on an annualized basis. An analysis and reconciliation of the Company’s business segment, product line and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Sales: Greatbatch Medical Cardiac/Neuromodulation $ 90,153 $ 80,005 $ 166,426 $ 166,785 Orthopaedic 35,481 37,865 74,452 74,296 Portable Medical 17,700 16,737 31,367 35,940 Vascular 12,907 15,257 23,263 28,307 Energy, Military, Environmental 16,545 21,352 34,255 39,483 Total Greatbatch Medical 172,786 171,216 329,763 344,811 QiG 2,741 865 7,788 1,551 Elimination of Intersegment Sales (a) (637 ) — (1,341 ) — Total sales $ 174,890 $ 172,081 $ 336,210 $ 346,362 (a) Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line. Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Segment income (loss) from operations: Greatbatch Medical $ 28,914 $ 32,439 $ 50,667 $ 67,567 QiG (7,002 ) (6,173 ) (12,452 ) (12,086 ) Total segment income from operations 21,912 26,266 38,215 55,481 Unallocated operating expenses (8,878 ) (6,727 ) (15,792 ) (13,418 ) Operating income as reported 13,034 19,539 22,423 42,063 Unallocated other expense (1,099 ) (1,407 ) (668 ) (1,870 ) Income before provision for income taxes $ 11,935 $ 18,132 $ 21,755 $ 40,193 Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Sales by geographic area: United States $ 75,041 $ 77,761 $ 145,557 $ 158,873 Non-Domestic locations: Puerto Rico 37,415 31,885 71,431 66,483 Belgium 16,018 17,650 33,385 33,629 Rest of world 46,416 44,785 85,837 87,377 Total sales $ 174,890 $ 172,081 $ 336,210 $ 346,362 Three customers accounted for a significant portion of the Company’s sales as follows: Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Customer A 20 % 17 % 21 % 19 % Customer B 18 % 17 % 18 % 16 % Customer C 12 % 12 % 13 % 12 % Total 50 % 46 % 52 % 47 % Long-lived tangible assets by geographic area are as follows (in thousands): As of July 3, 2015 January 2, 2015 United States $ 111,503 $ 113,851 Rest of world 41,210 31,074 Total $ 152,713 $ 144,925

Impact of Recently Issued Accou

Impact of Recently Issued Accounting Standards	6 Months Ended
	Jul. 03, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS	IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements. In July 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This ASU is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this ASU on its Condensed Consolidated Financial Statements. In April 2015, the FASB issued ASU No. 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs,” which changes the presentation of debt issuance costs in the financial statements. Under this ASU, the Company will present debt issuance costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. The guidance in this ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company will apply the new guidance retrospectively to all prior periods presented beginning in the first quarter of fiscal year 2016. As disclosed in Note 6 “Debt,” as of July 3, 2015 , the Company had $2.7 million of debt related deferred financing costs recorded within Other Assets in the Condensed Consolidated Balance Sheet, which will be reclassified as a deduction from Long-Term Debt upon adoption of this ASU. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU will supersede existing revenue recognition guidance. In July 2015, the FASB deferred for one year the effective date of the new standard to be effective for annual reporting periods beginning after December 15, 2017. Early application is permitted for all entities, but not before the original public entity effective date. This ASU allows two methods of adoption; a full retrospective approach where three years of financial information are presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. The Company is currently assessing the financial impact of adopting the new standard and the methods of adoption; however, given the scope of the new standard, the company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised guidance changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014, with early adoption permitted. This ASU is applicable for disposal transactions, if any, that the Company enters into after January 2, 2015. This ASU did not materially impact the Company’s Condensed Consolidated Financial Statements.

Accounting Policies (Policies)

Accounting Policies (Policies)	6 Months Ended
	Jul. 03, 2015
Accounting Policies [Abstract]
Interim Basis of Accounting	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented. The January 2, 2015 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015 .
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The second quarter and year-to-date periods of 2015 and 2014 each contained 13 weeks and 26 weeks, respectively, and ended on July 3, and July 4, respectively.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Long Lived Assets and Finite-Lived Intangible Assets	The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first six months of 2015 or 2014 .
Goodwill and Intangible Assets	Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero ” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples. Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach.
Cost And Equity Method Investments	The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other (Income) Expense, Net, unless separately stated.

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jul. 03, 2015
Business Combinations [Abstract]
Summary of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands): Assets acquired Current assets $ 10,670 Property, plant and equipment 1,131 Amortizing intangible assets 6,100 Goodwill 8,296 Total assets acquired 26,197 Liabilities assumed Current liabilities 4,842 Deferred income taxes 1,590 Total liabilities assumed 6,432 Net assets acquired $ 19,765
Summary of Finite-Lived Intangibles Assets Acquired	The purchase price was allocated to intangible assets as follows (dollars in thousands): Amortizing Intangible Assets Fair Value Assigned Weighted Average Amortization Period (Years) Weighted Average Discount Rate Technology $ 1,400 10 18% Customer lists 4,600 10 18% Trademarks and tradenames 100 2 18% $ 6,100 10 18%
Summary of Acquisition Pro Forma Results	The following pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Sales $ 174,890 $ 175,509 $ 336,210 $ 353,218 Net income 9,283 12,684 17,291 27,945 Earnings per share: Basic $ 0.36 $ 0.51 $ 0.68 $ 1.13 Diluted $ 0.35 $ 0.49 $ 0.66 $ 1.08

Supplemental Cash Flow Inform25

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jul. 03, 2015
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	Six Months Ended (in thousands) July 3, 2015 July 4, 2014 Noncash investing and financing activities: Common stock contributed to 401(k) Plan $ 3,920 $ 4,341 Property, plant and equipment purchases included in accounts payable 1,446 1,486

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 03, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories are comprised of the following (in thousands): As of July 3, 2015 January 2, 2015 Raw materials $ 82,061 $ 73,354 Work-in-process 43,478 38,930 Finished goods 14,554 16,958 Total $ 140,093 $ 129,242

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jul. 03, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Major Class	Amortizing intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Carrying Amount At July 3, 2015 Purchased technology and patents $ 95,776 $ (79,015 ) $ 1,966 $ 18,727 Customer lists 72,857 (34,974 ) 1,374 39,257 Other 4,534 (4,749 ) 803 588 Total amortizing intangible assets $ 173,167 $ (118,738 ) $ 4,143 $ 58,572 At January 2, 2015 Purchased technology and patents $ 95,776 $ (75,894 ) $ 1,966 $ 21,848 Customer lists 72,857 (31,460 ) 1,374 42,771 Other 4,534 (4,619 ) 803 718 Total amortizing intangible assets $ 173,167 $ (111,973 ) $ 4,143 $ 65,337
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense is comprised of the following (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Cost of sales $ 1,445 $ 1,566 $ 2,916 $ 3,129 Selling, general and administrative expenses 1,830 1,717 3,643 3,434 Research, development and engineering costs, net 103 200 206 401 Total intangible asset amortization expense $ 3,378 $ 3,483 $ 6,765 $ 6,964
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands): Estimated Amortization Expense Remainder of 2015 $ 6,222 2016 10,795 2017 9,520 2018 7,114 2019 5,431 Thereafter 19,490 Total estimated amortization expense $ 58,572
Schedule of Indefinite-Lived Intangible Assets and Goodwill	Indefinite-lived intangible assets are comprised of the following (in thousands): Trademarks and Tradenames At January 2, 2015 $ 20,288 At July 3, 2015 $ 20,288 The change in goodwill is as follows (in thousands): Greatbatch Medical QiG Total At January 2, 2015 $ 304,297 $ 50,096 $ 354,393 Foreign currency translation (286 ) — (286 ) At July 3, 2015 $ 304,011 $ 50,096 $ 354,107

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jul. 03, 2015
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt is comprised of the following (in thousands): As of July 3, 2015 January 2, 2015 Variable rate term loan $ 182,500 $ 187,500 Revolving line of credit — — Total debt 182,500 187,500 Less current portion of long-term debt 13,750 11,250 Total long-term debt $ 168,750 $ 176,250
Schedule of Interest Rate Swaps	Information regarding the Company’s outstanding interest rate swaps as of July 3, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Notional Amount Start Date End Date Pay Fixed Rate Current Receive Floating Rate Fair Value Balance Sheet Location Interest rate swap Cash flow $ 50,000 Feb 2013 Feb 2016 0.573 % 0.187 % $ (95 ) Accrued Expenses Interest rate swap Cash flow $ 90,000 Feb 2015 Sept 2019 1.921 % 0.187 % $ (1,488 ) Other Long-Term Liabilities
Schedule Of Maturities of Long-Term Debt	The expected future minimum principal payments under the Term Loan as of July 3, 2015 are as follows (in thousands): Remainder of 2015 $ 6,250 2016 16,250 2017 20,000 2018 20,000 2019 120,000 Total $ 182,500
Schedule of Deferred Financing Fees	The change in deferred financing fees is as follows (in thousands): At January 2, 2015 $ 3,087 Amortization during the period (387 ) At July 3, 2015 $ 2,700

Benefit Plans (Tables)

Benefit Plans (Tables)	6 Months Ended
	Jul. 03, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of Defined Benefit Plan, Change in Benefit Obligation	The change in net defined benefit plan liability is as follows (in thousands): At January 2, 2015 $ 2,406 Net defined benefit cost 207 Foreign currency translation (164 ) At July 3, 2015 $ 2,449
Schedule of Net Defined Benefit Cost	Net defined benefit cost is comprised of the following (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Service cost $ 78 $ 52 $ 157 $ 104 Interest cost 15 20 30 39 Amortization of net loss 12 5 26 11 Expected return on plan assets (3 ) — (6 ) — Net defined benefit cost $ 102 $ 77 $ 207 $ 154

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jul. 03, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Stock options $ 663 $ 612 $ 1,282 $ 1,216 Restricted stock and restricted stock units 1,746 1,601 3,380 3,158 401(k) Plan stock contribution 1,310 1,339 1,310 2,355 Total stock-based compensation expense $ 3,719 $ 3,552 $ 5,972 $ 6,729 Cost of sales $ 1,094 $ 1,147 $ 1,354 $ 2,058 Selling, general and administrative expenses 2,148 1,998 3,909 3,921 Research, development and engineering costs, net 477 407 709 750 Total stock-based compensation expense $ 3,719 $ 3,552 $ 5,972 $ 6,729
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average fair value and assumptions used to value options granted are as follows: Six Months Ended July 3, 2015 July 4, 2014 Weighted average fair value $ 12.18 $ 16.43 Risk-free interest rate 1.55 % 1.73 % Expected volatility 26 % 39 % Expected life (in years) 5 5 Expected dividend yield — % — %
Schedule of Share-based Compensation, Stock Options Activity	The following table summarizes time-vested stock option activity: Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 2, 2015 1,471,498 $ 25.32 Granted 301,547 49.20 Exercised (174,836 ) 23.41 Forfeited or expired (25,721 ) 37.94 Outstanding at July 3, 2015 1,572,488 $ 29.91 6.4 $ 37.1 Exercisable at July 3, 2015 1,115,959 $ 24.27 5.4 $ 32.6 The following table summarizes performance-vested stock option activity: Number of Performance- Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 2, 2015 118,839 $ 23.24 Exercised (50,255 ) 22.53 Outstanding at July 3, 2015 68,584 $ 23.76 3.0 $ 2.0 Exercisable at July 3, 2015 68,584 $ 23.76 3.0 $ 2.0
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 67,832 $ 36.22 Granted 42,497 49.52 Vested (8,831 ) 49.54 Forfeited (7,130 ) 42.15 Nonvested at July 3, 2015 94,368 $ 40.51 The following table summarizes performance-vested restricted stock and restricted stock unit activity: Performance- Vested Activity Weighted Average Fair Value Nonvested at January 2, 2015 716,163 $ 19.57 Granted 179,940 32.92 Vested (270,198 ) 15.30 Forfeited (25,599 ) 25.53 Nonvested at July 3, 2015 600,306 $ 25.24

Other Operating Expenses, Net (

Other Operating Expenses, Net (Tables)	6 Months Ended
	Jul. 03, 2015
Restructuring Cost and Reserve [Line Items]
Schedule of Other Operating Cost and Expense By Component	Other Operating Expenses, Net is comprised of the following (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 2014 investments in capacity and capabilities $ 6,051 $ 2,166 $ 12,738 $ 2,218 Orthopaedic optimization costs 518 1,187 991 36 2013 operating unit realignment — 32 — 1,035 Other consolidation and optimization income, net — (10 ) — (71 ) Acquisition and integration costs (income) 98 47 164 (381 ) Asset dispositions, severance and other 1,083 839 1,712 1,210 $ 7,750 $ 4,261 $ 15,605 $ 4,047
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ 1,163 $ — $ 1,066 $ 2,229 Restructuring charges 1,788 235 10,715 12,738 Write-offs — (235 ) — (235 ) Cash payments (949 ) — (10,328 ) (11,277 ) At July 3, 2015 $ 2,002 $ — $ 1,453 $ 3,455
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 2, 2015 $ — $ — $ 287 $ 287 Restructuring charges — 88 903 991 Write-offs — (88 ) — (88 ) Cash payments — — (1,034 ) (1,034 ) At July 3, 2015 $ — $ — $ 156 $ 156

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jul. 03, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability was comprised of the following (in thousands): At January 2, 2015 $ 660 Additions to warranty reserve 798 Warranty claims paid (102 ) At July 3, 2015 $ 1,356
Schedule of Future Minimum Rental Payments for Operating Leases	Minimum future estimated operating lease expenses are as follows (in thousands): Remainder of 2015 $ 3,077 2016 5,981 2017 3,910 2018 3,488 2019 3,418 Thereafter 13,937 Total estimated operating lease expense $ 33,811
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The impact to the Company’s results of operations from these forward contracts was as follows (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Addition (reduction) in cost of sales $ 420 $ 8 $ 664 $ (156 ) Ineffective portion of change in fair value — — — —
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Information regarding outstanding foreign currency contracts as of July 3, 2015 is as follows (dollars in thousands): Instrument Type of Hedge Aggregate Notional Amount Start Date End Date $/Peso Fair Value Balance Sheet Location FX Contract Cash flow $ 8,440 Jan 2015 Dec 2015 0.0734 $ (1,094 ) Accrued Expenses FX Contract Cash flow $ 1,574 Mar 2015 Dec 2015 0.0656 $ (61 ) Accrued Expenses FX Contract Cash flow $ 15,081 Jan 2016 Dec 2016 0.0656 $ (881 ) Accrued Expenses/Other Long-Term Liabilities

Earnings Per Share (EPS) (Table

Earnings Per Share (EPS) (Tables)	6 Months Ended
	Jul. 03, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Numerator for basic and diluted EPS: Net income $ 9,283 $ 12,348 $ 17,291 $ 27,270 Denominator for basic EPS: Weighted average shares outstanding 25,473 24,838 25,369 24,726 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 840 1,063 895 1,097 Denominator for diluted EPS 26,313 25,901 26,264 25,823 Basic EPS $ 0.36 $ 0.50 $ 0.68 $ 1.10 Diluted EPS $ 0.35 $ 0.48 $ 0.66 $ 1.06
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met: Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Time-vested stock options, restricted stock and restricted stock units 276,000 179,000 297,000 179,000 Performance-vested restricted stock units 59,600 — 55,800 —

Accumulated Other Comprehensi34

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jul. 03, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At April 3, 2015 $ (1,181 ) $ (3,480 ) $ 9,625 $ 4,964 $ 1,734 $ 6,698 Unrealized loss on cash flow hedges — (840 ) — (840 ) 295 (545 ) Realized loss on foreign currency hedges — 420 — 420 (147 ) 273 Realized loss on interest rate swap hedges — 281 — 281 (98 ) 183 Foreign currency translation gain — — 214 214 — 214 At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 2, 2015 $ (1,181 ) $ (2,558 ) $ 11,450 $ 7,711 $ 1,412 $ 9,123 Unrealized loss on cash flow hedges — (2,187 ) — (2,187 ) 766 (1,421 ) Realized loss on foreign currency hedges — 664 — 664 (232 ) 432 Realized loss on interest rate swap hedges — 462 — 462 (162 ) 300 Foreign currency translation loss — — (1,611 ) (1,611 ) — (1,611 ) At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At April 4, 2014 $ (672 ) $ (350 ) $ 16,134 $ 15,112 $ 505 $ 15,617 Unrealized gain on cash flow hedges — 18 — 18 (6 ) 12 Realized loss on foreign currency hedges — 8 — 8 (3 ) 5 Realized loss on interest rate swap hedges — 106 — 106 (37 ) 69 Foreign currency translation loss — — (393 ) (393 ) — (393 ) At July 4, 2014 $ (672 ) $ (218 ) $ 15,741 $ 14,851 $ 459 $ 15,310 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 3, 2014 $ (672 ) $ (468 ) $ 14,952 $ 13,812 $ 546 $ 14,358 Unrealized gain on cash flow hedges — 168 — 168 (59 ) 109 Realized gain on foreign currency hedges — (156 ) — (156 ) 55 (101 ) Realized loss on interest rate swap hedges — 238 — 238 (83 ) 155 Foreign currency translation gain — — 789 789 — 789 At July 4, 2014 $ (672 ) $ (218 ) $ 15,741 $ 14,851 $ 459 $ 15,310

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 03, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information regarding liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Measurements Using At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Description 2015 (Level 1) (Level 2) (Level 3) Liabilities Foreign currency contracts (Note 11) $ 2,036 $ — $ 2,036 $ — Interest rate swap (Note 6) 1,583 — 1,583 —

Business Segment, Geographic 36

Business Segment, Geographic and Concentration Risk Information (Tables)	6 Months Ended
	Jul. 03, 2015
Segment Reconciliation [Abstract]
Reconciliation of Revenue from Segments to Consolidated	Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands): Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Sales: Greatbatch Medical Cardiac/Neuromodulation $ 90,153 $ 80,005 $ 166,426 $ 166,785 Orthopaedic 35,481 37,865 74,452 74,296 Portable Medical 17,700 16,737 31,367 35,940 Vascular 12,907 15,257 23,263 28,307 Energy, Military, Environmental 16,545 21,352 34,255 39,483 Total Greatbatch Medical 172,786 171,216 329,763 344,811 QiG 2,741 865 7,788 1,551 Elimination of Intersegment Sales (a) (637 ) — (1,341 ) — Total sales $ 174,890 $ 172,081 $ 336,210 $ 346,362 (a) Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Segment income (loss) from operations: Greatbatch Medical $ 28,914 $ 32,439 $ 50,667 $ 67,567 QiG (7,002 ) (6,173 ) (12,452 ) (12,086 ) Total segment income from operations 21,912 26,266 38,215 55,481 Unallocated operating expenses (8,878 ) (6,727 ) (15,792 ) (13,418 ) Operating income as reported 13,034 19,539 22,423 42,063 Unallocated other expense (1,099 ) (1,407 ) (668 ) (1,870 ) Income before provision for income taxes $ 11,935 $ 18,132 $ 21,755 $ 40,193
Schedule of Revenue By Major Customers By Reporting Segments	Three customers accounted for a significant portion of the Company’s sales as follows: Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Customer A 20 % 17 % 21 % 19 % Customer B 18 % 17 % 18 % 16 % Customer C 12 % 12 % 13 % 12 % Total 50 % 46 % 52 % 47 %
Geographic Areas, Revenues from External Customers [Abstract]
Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area	Three Months Ended Six Months Ended July 3, 2015 July 4, 2014 July 3, 2015 July 4, 2014 Sales by geographic area: United States $ 75,041 $ 77,761 $ 145,557 $ 158,873 Non-Domestic locations: Puerto Rico 37,415 31,885 71,431 66,483 Belgium 16,018 17,650 33,385 33,629 Rest of world 46,416 44,785 85,837 87,377 Total sales $ 174,890 $ 172,081 $ 336,210 $ 346,362
Geographic Areas, Long-Lived Assets [Abstract]
Schedule of Long-Lived Assets By Geographical Areas	Long-lived tangible assets by geographic area are as follows (in thousands): As of July 3, 2015 January 2, 2015 United States $ 111,503 $ 113,851 Rest of world 41,210 31,074 Total $ 152,713 $ 144,925

Basis of Presentation (Details)

Basis of Presentation (Details)	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Accounting Policies [Abstract]
Fiscal Period Duration	91 days	91 days	182 days	182 days

Acquisition (Summary of Assets

Acquisition (Summary of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015	Aug. 12, 2014
Assets acquired
Goodwill	$ 354,107	$ 354,393
CCC [Member]
Assets acquired
Current assets			$ 10,670
Property, plant and equipment			1,131
Amortizing intangible assets			6,100
Goodwill			8,296
Total assets acquired			26,197
Liabilities assumed
Current liabilities			4,842
Deferred income taxes			1,590
Total liabilities assumed			6,432
Net assets acquired			$ 19,765

Acquisition (Summary of Finite-

Acquisition (Summary of Finite-Lived Intangible Assets Acquired) (Details) - Aug. 12, 2014 - CCC [Member] - USD ($) $ in Thousands	Total
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 6,100
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Technology And Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 1,400
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Royalty Rate (Percent)	3.00%
Customer Lists [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 4,600
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Customer Annual Attrition Rate	15.00%
Trademarks And Tradenames [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 100
Weighted Average Amortization Period (Years)	2 years
Weighted Average Discount Rate	18.00%
Royalty Rate (Percent)	0.50%

Acquisition (Summary of Acquisi

Acquisition (Summary of Acquisition Pro Forma Results) (Details) - CCC [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Business Acquisition [Line Items]
Sales	$ 174,890	$ 175,509	$ 336,210	$ 353,218
Net income	$ 9,283	$ 12,684	$ 17,291	$ 27,945
Earnings per share:
Basic (in dollars per share)	$ 0.36	$ 0.51	$ 0.68	$ 1.13
Diluted (in dollars per share)	$ 0.35	$ 0.49	$ 0.66	$ 1.08

Acquisition (Narrative) (Detail

Acquisition (Narrative) (Details) - Aug. 12, 2014 - CCC [Member] - USD ($) $ in Millions	Total
Business Acquisition [Line Items]
Effective Date of Acquisition	Aug. 12, 2014
Name of Acquired Entity	Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”)
Description of Acquired Entity	CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads.
Reason for Acquisition	This acquisition allows the Company to more broadly partner with development stage medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts.
Cash Paid	$ 19.8
Increase in Inventory	$ 0.3

Supplemental Cash Flow Inform42

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014
Noncash investing and financing activities:
Common stock contributed to 401(k) Plan	$ 3,920	$ 4,341
Property, plant and equipment purchases included in accounts payable	$ 1,446	$ 1,486

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Inventory Disclosure [Abstract]
Inventory, Raw Materials	$ 82,061	$ 73,354
Inventory, Work in Process	43,478	38,930
Inventory, Finished Goods	14,554	16,958
Total Inventories	$ 140,093	$ 129,242

Intangible Assets (Schedule of

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 173,167	$ 173,167
Finite-Lived Intangible Assets, Accumulated Amortization	(118,738)	(111,973)
Foreign Currency Translation	4,143	4,143
Amortizing Intangible Assets, Net	58,572	65,337
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	95,776	95,776
Finite-Lived Intangible Assets, Accumulated Amortization	(79,015)	(75,894)
Foreign Currency Translation	1,966	1,966
Amortizing Intangible Assets, Net	18,727	21,848
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	72,857	72,857
Finite-Lived Intangible Assets, Accumulated Amortization	(34,974)	(31,460)
Foreign Currency Translation	1,374	1,374
Amortizing Intangible Assets, Net	39,257	42,771
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,534	4,534
Finite-Lived Intangible Assets, Accumulated Amortization	(4,749)	(4,619)
Foreign Currency Translation	803	803
Amortizing Intangible Assets, Net	$ 588	$ 718

Intangible Assets (Schedule o45

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$ 3,378	$ 3,483	$ 6,765	$ 6,964
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	1,445	1,566	2,916	3,129
Selling General And Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	1,830	1,717	3,643	3,434
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$ 103	$ 200	$ 206	$ 401

Intangible Assets Intangible As

Intangible Assets Intangible Assets (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2015	$ 6,222
2,016	10,795
2,017	9,520
2,018	7,114
2,019	5,431
Thereafter	19,490
Amortizing Intangible Assets, Net	$ 58,572	$ 65,337

Intangible Assets (Schedule o47

Intangible Assets (Schedule of Indefinite-Lived Intangible Assets and Goodwill) (Details) $ in Thousands	6 Months Ended
	Jul. 03, 2015USD ($)
Indefinite-Lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning	$ 20,288
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending	20,288
Goodwill [Roll Forward]
Goodwill	354,393
Foreign currency translation	(286)
Goodwill	354,107
Greatbatch Medical [Member]
Goodwill [Roll Forward]
Goodwill	304,297
Foreign currency translation	(286)
Goodwill	304,011
QiG [Member]
Goodwill [Roll Forward]
Goodwill	50,096
Foreign currency translation	0
Goodwill	50,096
Trademarks And Tradenames [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning	20,288
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending	$ 20,288

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Debt Disclosure [Abstract]
Variable rate term loan	$ 182,500	$ 187,500
Revolving line of credit	0	0
Total debt	182,500	187,500
Less current portion of long-term debt	13,750	11,250
Total long-term debt	$ 168,750	$ 176,250

Debt (Credit Facility) (Details

Debt (Credit Facility) (Details)	6 Months Ended
	Jul. 03, 2015USD ($)	Jan. 02, 2015USD ($)
Line of Credit Facility [Abstract]
Credit Facility Maximum Borrowing Capacity	$ 300,000,000
Term Loan Maximum Borrowing Capacity	182,500,000	$ 187,500,000
Letter of Credit Subfacility Maximum Borrowing Capacity	15,000,000
Swingline Subfacility Maximum Borrowing Capacity	15,000,000
Credit Facility Borrowing Capacity Increase	$ 200,000,000
Credit Facility Expiration Date	Sep. 20, 2018
Line of Credit Expiration Date	Sep. 20, 2019
Maturity Date	Sep. 20, 2019
Collateral	The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories.
Credit Facility Interest Margin Above Prime Minimum	0.00%
Credit Facility Interest Margin Above Prime Maximum	0.75%
Credit Facility Interest Margin Above LIBOR Minimum	1.375%
Credit Facility Interest Margin Above LIBOR Maximum	2.75%
Swingline Interest Margin Above Prime Minimum	0.00%
Swingline Interest Margin Above Prime Maximum	0.75%
Line of Credit Facility Minimum Commitment Fee, Percentage	0.175%
Line of Credit Facility Maximum Commitment Fee, Percentage	0.25%
Credit Facility Aggregate Restricted Activities Limit	$ 300,000,000
Credit Facility Maximum Permitted Acquisitions	250,000,000
Credit Facility Maximum Investment Purchases	100,000,000
Credit Facility Maximum Stock Repurchase and Dividends Declared	150,000,000
Credit Facility Maximum Foreign Subsidiary Investment	$ 20,000,000
Line of Credit Adjustment to Limitations to Maximum Leverage Ratio	2.75
Credit Facility Available Restriction	100.00%
Credit Facility Remaining Restricted Activities Limit	$ 293,000,000
Credit Facility Maximum Other Investment Purchases Remaining	$ 93,000,000
Line of Credit Covenant, Adjusted EBITDA to Interest Expense, Ratio Required	3
Line of Credit Covenant, Leverage Ratio, Maximum	4.5
Line of Credit Covenant, Leverage Ratio, Maximum, As of Covenant Restrictive Effective Date	4.25
Total Leverage Covenant Restriction Effective Date	Jan. 2, 2016
Debt Instrument, Covenant Compliance	As of July 3, 2015, the Company was in compliance with all covenants under the Credit Facility.
Debt Weighted Average Interest Rate	1.56%
Unused Borrowing Capacity	$ 300,000,000

Debt (Schedule of Interest Rate

Debt (Schedule of Interest Rate Swaps and Details) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014	Dec. 28, 2012
Derivative [Line Items]
Interest Expense	$ 1,206	$ 1,073	$ 2,326	$ 2,157
Interest Rate Swap [Member]
Derivative [Line Items]
Description Of Interest Rate Risk Exposure			From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility.
Description Of Interest Rate Cash Flow Hedge Accounting Method			These swaps are being accounted for as cash flow hedges.
Gain (Loss) Recognized In Income Ineffective Portion			$ 0	0
Interest Expense			500	$ 200
Interest Rate Swap 1 [Member]
Derivative [Line Items]
Derivative, Term of Contract					3 years
Notional Amount	50,000		50,000		$ 150,000
Annual Notional Amortizing Amount	$ 50,000		$ 50,000
Description Of Interest Rate Cash Flow Hedge Accounting Method			Cash flow
Type of Hedge			Interest rate swap
Pay Fixed Interest Rate	0.573%		0.573%
Current Receive Variable Interest Rate	0.187%		0.187%
Interest Rate Swap 1 [Member] | Accrued Expenses [Member]
Derivative [Line Items]
Fair Value	$ (95)		$ (95)
Interest Rate Swap 2 [Member]
Derivative [Line Items]
Notional Amount	90,000		90,000
Annual Notional Amortizing Amount	$ 10,000		$ 10,000
Notional Amortizing Start Date			Feb. 21, 2017
End Date			Sep. 20, 2019
Description Of Interest Rate Cash Flow Hedge Accounting Method			Cash flow
Type of Hedge			Interest rate swap
Pay Fixed Interest Rate	1.921%		1.921%
Current Receive Variable Interest Rate	0.187%		0.187%
Interest Rate Swap 2 [Member] | Other Long-Term Liabilities [Member]
Derivative [Line Items]
Fair Value	$ (1,488)		$ (1,488)
Interest Rate Swap 2a [Member]
Derivative [Line Items]
Notional Amount	45,000		$ 45,000
Start Date			Feb. 20, 2015
Interest Rate Swap 2b [Member]
Derivative [Line Items]
Notional Amount	$ 45,000		$ 45,000
Start Date			Feb. 22, 2016

Debt (Schedule of Maturities of

Debt (Schedule of Maturities of Long-Term Debt) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Long-term Debt, Fiscal Year Maturity [Abstract]
Remainder of 2015	$ 6,250
2,016	16,250
2,017	20,000
2,018	20,000
2,019	120,000
Total debt	$ 182,500	$ 187,500

Debt (Schedule of Deferred Fina

Debt (Schedule of Deferred Financing Fees) (Details) $ in Thousands	6 Months Ended
	Jul. 03, 2015USD ($)
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	$ 3,087
Amortization during the period	(387)
Deferred Finance Costs, Net, Ending Balance	$ 2,700

Benefit Plans (Schedule of Defi

Benefit Plans (Schedule of Defined Benefit Plan, Change in Benefit Obligation) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
At January 2, 2015			$ 2,406
Net defined benefit cost	$ 102	$ 77	207	$ 154
Foreign currency translation			(164)
At July 3, 2015	$ 2,449		$ 2,449

Benefit Plans (Schedule of Net

Benefit Plans (Schedule of Net Defined Benefit Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Service cost	$ 78	$ 52	$ 157	$ 104
Interest cost	15	20	30	39
Amortization of net loss	12	5	26	11
Defined Benefit Plan, Expected Return on Plan Assets	(3)	0	(6)	0
Net defined benefit cost	$ 102	$ 77	$ 207	$ 154

Stock-Based Compensation (Alloc

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 3,719	$ 3,552	$ 5,972	$ 6,729
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	663	612	1,282	1,216
Restricted Stock And Unit Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,746	1,601	3,380	3,158
Retirement Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,310	1,339	1,310	2,355
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,094	1,147	1,354	2,058
Selling General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	2,148	1,998	3,909	3,921
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 477	$ 407	$ 709	$ 750

Stock-Based Compensation (Valua

Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares	6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value	$ 12.18	$ 16.43
Risk-free interest rate	1.55%	1.73%
Expected volatility	26.00%	39.00%
Expected life (in years)	5 years	5 years
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Options Activity) (Details) - Jul. 03, 2015 - USD ($) $ / shares in Units, $ in Millions	Total
Stock Options Time Based [Member]
Stock Option Activity (in shares)
Options Outstanding, Beginning	1,471,498
Granted	301,547
Exercised	(174,836)
Forfeited or expired	(25,721)
Options Outstanding, Ending	1,572,488
Options Exercisable	1,115,959
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning	$ 25.32
Granted	49.20
Exercised	23.41
Forfeited or expired	37.94
Options Outstanding, Ending	29.91
Options Exercisable	$ 24.27
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	6 years 5 months 8 days
Options Exercisable, Weighted Average Remaining Contractual Term	5 years 4 months 20 days
Options Outstanding, Intrinsic Value	$ 37.1
Options Exercisable, Intrinsic Value	$ 32.6
Stock Options Performance Based [Member]
Stock Option Activity (in shares)
Options Outstanding, Beginning	118,839
Exercised	(50,255)
Options Outstanding, Ending	68,584
Options Exercisable	68,584
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning	$ 23.24
Exercised	22.53
Options Outstanding, Ending	23.76
Options Exercisable	$ 23.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	3 years
Options Exercisable, Weighted Average Remaining Contractual Term	3 years
Options Outstanding, Intrinsic Value	$ 2
Options Exercisable, Intrinsic Value	$ 2

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) - 6 months ended Jul. 03, 2015 - $ / shares	Total
Restricted Stock And Restricted Stock Units Time Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning	67,832
Granted	42,497
Vested	(8,831)
Forfeited	(7,130)
Nonvested, Ending	94,368
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning	$ 36.22
Granted	49.52
Vested	49.54
Forfeited	42.15
Nonvested, Ending	$ 40.51
Restricted Stock And Restricted Stock Units Performance Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning	716,163
Granted	179,940
Vested	(270,198)
Forfeited	(25,599)
Nonvested, Ending	600,306
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning	$ 19.57
Granted	32.92
Vested	15.30
Forfeited	25.53
Nonvested, Ending	$ 25.24

Other Operating Expenses, Net59

Other Operating Expenses, Net (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	$ 7,750	$ 4,261	$ 15,605	$ 4,047
Investments in Capacity and Capabilities [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	6,051	2,166	12,738	2,218
Orthopaedic Facility Optimization [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	518	1,187	991	36
Operating Unit Realignment [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	0	32	0	1,035
Other Restructuring [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	0	(10)	0	(71)
Acquisition And Integration Costs [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	98	47	164	(381)
Asset Dispositions Severance And Other [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating Expenses (Income), Net	$ 1,083	$ 839	$ 1,712	$ 1,210

Other Operating Expenses, Net60

Other Operating Expenses, Net (Schedule of Restructuring Reserve By Type of Cost) (Details) $ in Thousands	6 Months Ended
	Jul. 03, 2015USD ($)
Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 2,229
Restructuring charges	12,738
Write-offs	(235)
Cash payments	(11,277)
Restructuring Reserve, Ending Balance	3,455
Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	287
Restructuring charges	991
Write-offs	(88)
Cash payments	(1,034)
Restructuring Reserve, Ending Balance	156
Severance And Retention [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,163
Restructuring charges	1,788
Write-offs	0
Cash payments	(949)
Restructuring Reserve, Ending Balance	2,002
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Write-offs	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	235
Write-offs	(235)
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	88
Write-offs	(88)
Cash payments	0
Restructuring Reserve, Ending Balance	0
Other Restructuring [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,066
Restructuring charges	10,715
Write-offs	0
Cash payments	(10,328)
Restructuring Reserve, Ending Balance	1,453
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	287
Restructuring charges	903
Write-offs	0
Cash payments	(1,034)
Restructuring Reserve, Ending Balance	$ 156

Other Operating Expenses, Net61

Other Operating Expenses, Net (Narrative) (Details) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 03, 2015USD ($)	Apr. 03, 2015	Jan. 02, 2015USD ($)	Jul. 03, 2015USD ($)departmental_groupbuilding	Jul. 04, 2014USD ($)	Jan. 02, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					$ 0.6
Greatbatch Medical [Member]
Restructuring Cost and Reserve [Line Items]
Number of Sales and Marketing Groups | departmental_group				1
Number of Operations Groups | departmental_group				1
Nuvectra [Member] | Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	$ 1.5			$ 1.5
Nuvectra [Member] | Minimum [Member] | Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	10			10
Nuvectra [Member] | Maximum [Member] | Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	12			$ 12
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date				2,014
Restructuring And Related Activities Capital Expenditures Incurred To Date	17			$ 17
Restructuring and Related Cost, Cost Incurred to Date	21.7			21.7
Investments in Capacity and Capabilities [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	25			25
Restructuring and Related Cost, Expected Cost	29			29
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	7			7
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	2			2
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	20			20
Investments in Capacity and Capabilities [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	28			28
Restructuring and Related Cost, Expected Cost	34			34
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	9			9
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	3			3
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	22			$ 22
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date				2,010
Restructuring And Related Activities Capital Expenditures Incurred To Date	25.4			$ 25.4
Restructuring and Related Cost, Cost Incurred to Date	43.5			$ 43.5
Restructuring and Related Costs, Facility Consolidations | building				2
Gain (Loss) on Disposition of Business					$ 2.7
Assets Transferred to Held for Sale						$ 2.1
Impairment of Long-Lived Assets to be Disposed of			$ 0.4
Proceeds from Sale of Property Held for Sale	0.6
Gain (Loss) on Disposition of Assets Held for Sale	0
Initiatives, Expected Period of Completion		2 years
Orthopaedic Facility Optimization [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	11			$ 11
Orthopaedic Facility Optimization [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	13			13
Orthopaedic Facility Optimization [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	30			30
Restructuring and Related Cost, Expected Cost	45			45
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	21			21
Orthopaedic Facility Optimization [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	35			35
Restructuring and Related Cost, Expected Cost	48			48
Orthopaedic Facility Optimization [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	24			$ 24
Operating Unit Realignment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date				2,013
Restructuring and Related Cost, Cost Incurred to Date	6.6			$ 6.6
Operating Unit Realignment [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	5			5
Operating Unit Realignment [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	$ 1.6			$ 1.6
Business Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Other Cost and Expense, Operating						$ 1.2

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	20.50%	32.20%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$ 1
Unrecognized Tax Benefits	1.9
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0.5
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 1.5

Commitments and Contingencies63

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	6 Months Ended
	Jul. 03, 2015USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
At January 2, 2015	$ 660
Additions to warranty reserve	798
Warranty claims paid	(102)
At July 3, 2015	$ 1,356

Commitments and Contingencies64

Commitments and Contingencies (Schedule of Future Minimum Rental Payments for Operating Leases) (Details) $ in Thousands	Jul. 03, 2015USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Remainder of 2015	$ 3,077
2,016	5,981
2,017	3,910
2,018	3,488
2,019	3,418
Thereafter	13,937
Total estimated operating lease expense	$ 33,811

Commitments and Contingencies65

Commitments and Contingencies (Foreign Currency Contracts) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015USD ($)	Jul. 04, 2014USD ($)	Jul. 03, 2015USD ($)	Jul. 04, 2014USD ($)
Foreign Currency Cash Flow Hedges [Abstract]
Addition (reduction) in cost of sales	$ 420	$ 8	$ 664	$ (156)
Ineffective portion of change in fair value	0	$ 0	$ 0	$ 0
FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument			FX Contract
Aggregate Notional Amount	$ 8,440		$ 8,440
Start Date			Jan. 1, 2015
End Date			Dec. 31, 2015
$/Peso	0.0734		0.0734
FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument			FX Contract
Aggregate Notional Amount	$ 1,574		$ 1,574
Start Date			Mar. 1, 2015
End Date			Dec. 31, 2015
$/Peso	0.0656		0.0656
FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument			FX Contract
Aggregate Notional Amount	$ 15,081		$ 15,081
Start Date			Jan. 1, 2016
End Date			Dec. 31, 2016
$/Peso	0.0656		0.0656
Accrued Expenses [Member] | FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	$ (1,094)		$ (1,094)
Accrued Expenses [Member] | FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	(61)		(61)
Accrued Expenses and Other Long-Term Liabilities [Member] | FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	$ (881)		$ (881)

Commitments and Contingencies66

Commitments and Contingencies (Narrative) (Details) - Jul. 03, 2015 - USD ($) $ in Thousands	Total
Commitments and Contingencies Disclosure [Abstract]
Product Warranty Description	The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Purchase Commitments Description	Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms; however, these orders are normally cancelable without penalty.
Remaining Minimum Amount Committed	$ 39,100
Foreign Currency Contracts Description	The Company has entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its Tijuana, Mexico facility.
Maximum Aggregate Loss Under Medical Stop Loss Insurance Per Employee	$ 250
Self-Insurance Medical Liability	$ 1,400

Earnings Per Share (EPS) (Detai

Earnings Per Share (EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income	$ 9,283	$ 12,348	$ 17,291	$ 27,270
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic	25,473,000	24,838,000	25,369,000	24,726,000
Effect of dilutive securities stock options, restricted stock and restricted stock units	840,000	1,063,000	895,000	1,097,000
Denominator for diluted EPS	26,313,000	25,901,000	26,264,000	25,823,000
Basic EPS (in dollars per share)	$ 0.36	$ 0.50	$ 0.68	$ 1.10
Diluted EPS (in dollars per share)	$ 0.35	$ 0.48	$ 0.66	$ 1.06
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units	276,000	179,000	297,000	179,000
Performance-vested stock options and restricted stock units	59,600	0	55,800	0

Accumulated Other Comprehensi68

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Defined Benefit Plan Liability
Defined Benefit Plan Liability, Beginning	$ (1,181)	$ (672)	$ (1,181)	$ (672)
Defined Benefit Plan Liability, Ending	(1,181)	(672)	(1,181)	(672)
Cash Flow Hedges
Cash Flow Hedges, Beginning	(3,480)	(350)	(2,558)	(468)
Unrealized loss on cash flow hedges	(840)	18	(2,187)	168
Realized gain loss on foreign currency hedges - before tax	420	8	664	(156)
Realized gain loss on interest rate swaps - before tax	281	106	462	238
Cash Flow Hedges, End	(3,619)	(218)	(3,619)	(218)
Foreign Currency Translation Adjustment
Foreign Currency Translation Adjustment, Beginning	9,625	16,134	11,450	14,952
Net foreign currency translation gain (loss)	214	(393)	(1,611)	789
Foreign Currency Translation Adjustment, End	9,839	15,741	9,839	15,741
Total Pre-Tax Amount
Total Pre-Tax Amount, Beginning	4,964	15,112	7,711	13,812
Unrealized loss on cash flow hedges	(840)	18	(2,187)	168
Realized gain loss on foreign currency hedges - before tax	420	8	664	(156)
Realized gain loss on interest rate swaps - before tax	281	106	462	238
Net foreign currency translation gain (loss)	214	(393)	(1,611)	789
Total Pre-Tax Amount, End	5,039	14,851	5,039	14,851
Tax
Tax, Beginning	1,734	505	1,412	546
Unrealized gain (loss) on cash flow hedges	295	(6)	766	(59)
Realized gain loss on foreign currency contracts - tax	(147)	(3)	(232)	55
Realized gain loss on interest rate swap hedges - tax	(98)	(37)	(162)	(83)
Net foreign currency translation gain (loss)	0	0	0	0
Tax, End	1,784	459	1,784	459
Net-of-Tax Amount
Total Net-of-Tax Amount, Beginning	6,698	15,617	9,123	14,358
Unrealized gain (loss) on cash flow hedges, net of tax	(545)	12	(1,421)	109
Realized gain loss on foreign currency hedges, net of tax	273	5	432	(101)
Realized gain loss on interest rate swap hedges, net of tax	183	69	300	155
Foreign currency translation gain (loss)	214	(393)	(1,611)	789
Total Net-of-Tax Amount, End	$ 6,823	$ 15,310	$ 6,823	$ 15,310

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] $ in Thousands	Jul. 03, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	$ 2,036
Interest rate swap	1,583
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0
Interest rate swap	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	2,036
Interest rate swap	1,583
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0
Interest rate swap	$ 0

Fair Value Measurements Fair 70

Fair Value Measurements Fair Value Measurements (Narrative) (Details) - USD ($)	6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jan. 02, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified	$ 1,500,000
Long-lived asset impairment loss	0	$ 0
Goodwill impairment loss	0	0
Indefinite-lived intangible assets (excluding goodwill) impairment loss	0	0
Equity method investments, carrying value	19,500,000		$ 14,500,000
Cost-method investment impairment loss	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Net gain on equity method investments	$ 500,000	$ 800,000
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Equity method investment ownership (percent)	7.30%

Business Segment, Geographic 71

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$ 174,890	$ 172,081	$ 336,210	$ 346,362
Greatbatch Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	172,786	171,216	329,763	344,811
Greatbatch Medical [Member] | Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	90,153	80,005	166,426	166,785
Greatbatch Medical [Member] | Orthopaedic [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	35,481	37,865	74,452	74,296
Greatbatch Medical [Member] | Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	17,700	16,737	31,367	35,940
Greatbatch Medical [Member] | Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	12,907	15,257	23,263	28,307
Greatbatch Medical [Member] | EME and Other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	16,545	21,352	34,255	39,483
QiG [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	2,741	865	7,788	1,551
Intersegment Eliminations [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$ (637)	$ 0	$ (1,341)	$ 0

Business Segment, Geographic 72

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Segment Reporting Information [Line Items]
Operating income as reported	$ 13,034	$ 19,539	$ 22,423	$ 42,063
Unallocated other expense	(1,099)	(1,407)	(668)	(1,870)
Income before provision for income taxes	11,935	18,132	21,755	40,193
Greatbatch Medical [Member]
Segment Reporting Information [Line Items]
Operating income as reported	28,914	32,439	50,667	67,567
QiG [Member]
Segment Reporting Information [Line Items]
Operating income as reported	(7,002)	(6,173)	(12,452)	(12,086)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income as reported	21,912	26,266	38,215	55,481
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating income as reported	$ (8,878)	$ (6,727)	$ (15,792)	$ (13,418)

Business Segment, Geographic 73

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Revenue, Major Customer [Line Items]
Sales Revenue, Net	$ 174,890	$ 172,081	$ 336,210	$ 346,362
UNITED STATES
Revenue, Major Customer [Line Items]
Sales Revenue, Net	75,041	77,761	145,557	158,873
PUERTO RICO
Revenue, Major Customer [Line Items]
Sales Revenue, Net	37,415	31,885	71,431	66,483
BELGIUM
Revenue, Major Customer [Line Items]
Sales Revenue, Net	16,018	17,650	33,385	33,629
Rest Of World [Member]
Revenue, Major Customer [Line Items]
Sales Revenue, Net	$ 46,416	$ 44,785	$ 85,837	$ 87,377

Business Segment, Geographic 74

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue By Major Customers By Reporting Segments) (Details) - customer	3 Months Ended		6 Months Ended
	Jul. 03, 2015	Jul. 04, 2014	Jul. 03, 2015	Jul. 04, 2014
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	50.00%	46.00%	52.00%	47.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	20.00%	17.00%	21.00%	19.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	18.00%	17.00%	18.00%	16.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	12.00%	12.00%	13.00%	12.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration risk, number of customers			3

Business Segment, Geographic 75

Business Segment, Geographic And Concentration Risk Information (Schedule of Long-Lived Assets By Geographical Areas) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$ 152,713	$ 144,925
UNITED STATES
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	111,503	113,851
Rest Of World [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$ 41,210	$ 31,074

Business Segment, Geographic 76

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Narrative) (Details) - Jul. 03, 2015 $ in Millions	USD ($)LLCSegment
Segment Reporting Information [Line Items]
Number of Reportable Segments | Segment	2
QiG [Member]
Segment Reporting Information [Line Items]
Number of Ownership Interests | LLC	2
Liability of Expenses Incurred (percent)	100.00%
FDA Submission Date	Dec. 16, 2013
CE Submission Date	Jan. 10, 2014
CE Approval Date	Jun. 17, 2014
Minimum [Member] | QiG [Member]
Segment Reporting Information [Line Items]
Parent Ownership Percentage	89.00%
Nuvectra [Member] | Spinoff [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Restructuring and Related Cost, Expected Cost	$ 10
Restructuring and Related Costs, Estimated Annual Future Operating Cost Savings	12
Nuvectra [Member] | Spinoff [Member] | Maximum [Member]
Segment Reporting Information [Line Items]
Restructuring and Related Cost, Expected Cost	12
Restructuring and Related Costs, Estimated Annual Future Operating Cost Savings	$ 16

Impact of Recently Issued Acc77

Impact of Recently Issued Accounting Standards Impact of Recently Issued Accounting Standards (Narrative) (Details) - USD ($) $ in Thousands	Jul. 03, 2015	Jan. 02, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred finance costs, net	$ 2,700	$ 3,087